These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8914817)

  • 21. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
    Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14.
    Jakob F; Seufert J; Sarrazin C; Schneider D; Köhrle J; Tony HP
    Biochem Biophys Res Commun; 1994 Mar; 199(2):531-9. PubMed ID: 7510956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
    Potter AJ; Rabinovitch PS
    Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
    Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
    Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumour drugs impede DNA uncoiling by topoisomerase I.
    Koster DA; Palle K; Bot ES; Bjornsti MA; Dekker NH
    Nature; 2007 Jul; 448(7150):213-7. PubMed ID: 17589503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of topoisomerase I/DNA complexes in patients administered topotecan.
    Subramanian D; Kraut E; Staubus A; Young DC; Muller MT
    Cancer Res; 1995 May; 55(10):2097-103. PubMed ID: 7743509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells.
    Hsiang YH; Wu HY; Liu LF
    Cancer Res; 1988 Jun; 48(11):3230-5. PubMed ID: 2835157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
    Pizao PE; Smitskamp-Wilms E; Van Ark-Otte J; Beijnen JH; Peters GJ; Pinedo HM; Giaccone G
    Biochem Pharmacol; 1994 Sep; 48(6):1145-54. PubMed ID: 7945408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.
    Zini N; Santi S; Ognibene A; Bavelloni A; Neri LM; Valmori A; Mariani E; Negri C; Astaldi-Ricotti GC; Maraldi NM
    Exp Cell Res; 1994 Feb; 210(2):336-48. PubMed ID: 8299728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells.
    Woessner RD; Mattern MR; Mirabelli CK; Johnson RK; Drake FH
    Cell Growth Differ; 1991 Apr; 2(4):209-14. PubMed ID: 1651102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The synergistic antitumor effects of berberine alpha-hydroxy-beta-decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase].
    Lin J; Wang X
    Yao Xue Xue Bao; 2011 Apr; 46(4):390-4. PubMed ID: 21751491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.
    Baker SD; Wadkins RM; Stewart CF; Beck WT; Danks MK
    Cytometry; 1995 Feb; 19(2):134-45. PubMed ID: 7743894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
    Nair J; Traganos F; Tse-Dinh YC
    Anticancer Res; 2000; 20(6B):4183-8. PubMed ID: 11205246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunocytometric determination of the alpha and beta isoforms of human DNA topoisomerase II: influence of different fixatives.
    Prosperi E; Negri C; Bottiroli G; Astaldi Ricotti GC
    Anal Cell Pathol; 1996 Mar; 10(2):137-48. PubMed ID: 8721955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA topoisomerase inhibitors.
    Capranico G; Giaccone G; Zunino F; Garattini S; D'Incalci M
    Cancer Chemother Biol Response Modif; 1994; 15():67-86. PubMed ID: 7779607
    [No Abstract]   [Full Text] [Related]  

  • 40. Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
    Poot M; Epe B; Hoehn H
    Mutat Res; 1992 Nov; 270(2):185-9. PubMed ID: 1383735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.